TBPN: "The Great Peptide Debate"

Guests: Martin Shkreli ("Pharma Bro") & Max Marchione (Superpower)
Hosts: John Coogan & Jordi Hays
Date: March 23, 2026

Overview

This episode of TBPN centers on one of Silicon Valley’s buzziest health trends: peptides—bioactive molecules increasingly used for wellness, optimization, and chronic disease management. Host John Coogan, with co-host Jordi Hays, orchestrates a spirited, civil debate between two prominent voices: Martin Shkreli, infamous biotech entrepreneur and pharmaceutical industry insider, and Max Marchione, founder of the peptide-forward health startup Superpower. The central theme explores the legitimacy, safety, and regulation of peptides—with a particular focus on gray-market access versus formal clinical oversight, the role of the FDA, and the clash between pharmaceutical orthodoxy and biohacker enthusiasm.

Introduction & Core Theses

[00:00–02:28]

• Martin Shkreli ("Pharma Bro") introduces himself as a drug industry insider, expressing skepticism and concern about the “peptide craze,” framing it as driven by “psychological issues” (00:43), distrust of institutions, and a lack of scientific rigor.

  • Notable Quote:
    “I’m very concerned about the peptide craze. I think it comes mostly out of psychological issues—which we’ll discuss. The need for identity control, distrust of institutions. All kinds of things like that are leading to what we’re seeing today.” — Martin Shkreli [01:16]

• Max Marchione positions himself as a former skeptic-turned-believer. He highlights the failures of the current health system in prevention and optimization, the value of “hundreds of clinical vignettes,” but acknowledges more research is needed.

  • Notable Quote:
    “Now that injecting is normal, now that wellness and optimization are normal—not just treating disease—and now that we have AI…I think peptides are exciting.” — Max Marchione [01:58]

Framing the Debate: What Are Peptides?

[02:28–04:00]

• John tries to clarify the conversation: “Peptides” encompasses a spectrum—from regulated therapies like Ozempic to unregulated ‘stacks’ used by fitness enthusiasts.

• Martin argues that peptides, as a drug class, are “the worst of both worlds” (small molecules vs. antibodies), traditionally avoided in pharma due to weaknesses (03:13). He calls their popularization “humorous to anybody who actually understands pharma.”

  • Notable Quote:
    “Peptides are sort of the worst of both worlds. So the idea that we’ve taken this kind of last place drug class and then turned that into the standard bearer for do-it-yourself medicine is kind of humorous to anybody who actually understands pharma.” — Martin Shkreli [03:25]

• Max pushes back, highlighting GLP1 receptor agonists (like Ozempic) as transformative peptide drugs. He argues naturally occurring peptides can be impactful but are hard to patent, contrasting them with human-designed small molecules (04:00–05:08).

Safety, Legality, and the Role of the Gray Market

[05:45–08:04]

• Discussion zeroes in on non-FDA-approved peptides sourced online (e.g., “Chinese peptides” or “Reddit peptides”).

• Martin: Frames this as piracy and intellectual property theft, posing a risk to innovation and patient safety. He compares the scenario to pirating music—a practice with devastating ecosystem effects. He condemns off-label or pre-approval use, arguing for IP and patient safety.

  • Notable Quote:
    “Why do you have a right to pirate somebody’s intellectual property?...You want to steal it, you want to work with the Chinese company stealing it, I mean, that’s not good for America...If you keep stealing them and pirating them...you'd stop having drugs. The same way pirating music would have huge ramifications for the music ecosystem.”—Martin Shkreli [06:07]

• Max: Agrees with avoiding outright patent violations and “dodgy supply chains,” but notes that much of the user base for peptides is not just coastal tech elites but across the US. He proposes that “legalizing” certain compounds could minimize harm compared to gray markets, especially via compounding pharmacies (08:04–09:10).

The BPC-157 Controversy: Anecdote vs. Evidence

[09:19–16:17]

• Core Disagreement: Should clinics and physicians offer peptides like BPC-157, which have large anecdotal followings but little RCT (randomized controlled trial) evidence?

  • Max: Argues for real-world evidence: “Thousands of doctors prescribe this…millions have taken this… their lives change.” He positions anecdote and clinical vignettes as signals that should not be ignored, especially for compounds like BPC-157 (09:19–11:58).
    • Memorable Moment: Max shares emotional personal stories about improvements in his father's and co-founder’s health, attributing it to BPC-157 (15:05–15:58).
  • Martin: Calls BPC-157 “the biggest scam I’ve ever seen,” noting the drug was developed and tested in Croatia, never got positive results in clinical trials, and all published research comes from one laboratory (12:43–13:45). He asserts any benefit is pure placebo and challenges Max to fund RCTs to prove efficacy ("Put your money where your mouth is" [16:03]).
    • Notable Quote:
      “BPC-157 is the biggest scam I’ve ever seen. It does absolutely nothing…There’s no plausible physiological basis for it to work. … Make BPC in cGMP conditions and go do a clinical trial—and you can be a trillion-dollar company like Eli Lilly. Instead you can putz around buying fake Chinese stuff and then injecting yourself and dreaming that you’re doing well.” — Martin Shkreli [12:43–13:45]

• Max: Says Superpower is in the process of setting up a clinical trial (“We will put our money where our mouth is” [16:16–16:37]).

• Martin: Skeptical about results—“I would bet anything, no trial of BPC would work” (19:04).

Broader Debate on Regulation: FDA, Patents, and Market Safety

[17:22–24:33]

• Hosts ask about the feasibility of Silicon Valley–backed clinical trials.

  • Martin: Many private biotechs exist, but most wouldn't pursue BPC-157 due to lack of substantive evidence. [17:51–18:12]

• Max: Argues that not all progress comes from RCTs—sometimes clinical observation (“signals”) should merit regulatory flexibility. He wants several Category 2 peptides given compounding rights when there are strong signals of safety and efficacy, reducing net harm compared to unregulated markets (19:20–24:33).

  • Notable Quote:
    “This isn’t a debate between no peptide and legal—it’s a debate between gray market or white market. … White market is net less harm, net higher benefit for the US people.” — Max Marchione [23:05–23:15]

• Martin: Insists regulatory rigor protects the public, “the government exists to help protect people from themselves and their own stupidity” (29:54–31:05). He frames SV enthusiasm as “wanting to play Dr. House today.”

  • Notable Quote:
    “We shouldn’t normalize making drugs in your bathtub. … Medicine has progressed dramatically thanks to the capitalist system and the biopharmaceutical system in league with the FDA, which doesn’t always get it right, but is quite good.” — Martin Shkreli [29:54–31:05]

• Debate on Thymosin Alpha 1:

  • Max: Calls attention to peptides like Thymosin Alpha 1 (approved in 35 countries) but rarely pursued in US pharma due to patent difficulties and economics (19:43–21:05).
  • Martin: Reiterates pharma can monetize even hard-to-patent compounds, via orphan exclusivity or molecular modification (20:27–21:01).

Is the FDA Efficient? Should We Change Regulation?

[25:38–28:33]

• John: Pushes Martin on whether the FDA is perfect, reflecting broader public skepticism of regulatory bottlenecks.
• Martin: Defends the FDA as “pretty good…one [part of government] I do like” ([26:13]), insists their framework works for the public good.
• Max: Asserts the genie can’t be put back in the bottle (27:02). Believes regulation should adapt to widespread gray-market use for harm reduction, rather than total prohibition.

Final Arguments & Risks

[28:45–32:30]

• Hosts: Ask: what are the actual risks, if peptides are so weak or ineffective?
  • Martin: Argues against normalizing DIY drug manufacturing, warns against misplaced individualism and the risk of self-experimentation. Emphasizes the achievements of regulated pharma; notes most users are healthy people seeking optimization rather than those with real illness (29:54–31:05).
• Max: Clarifies he’s not anti–FDA, but believes the system isn’t complete—calls for regulatory adaptation in light of new data, science, and dangerous gray markets (31:17–32:26).

Closing Statements

[32:26–32:44]

• Martin: “Pharma did try to develop BPC and failed” (32:30).
• Max: Superpower and partners are taking a handful of peptides through clinical trials and support FDA efforts to legalize those with strongest safety/efficacy signals (31:17, 32:26).

Notable/Memorable Moments

• Martin’s withering skepticism about peptides as a drug class:
  “To start to move away from evidence-based medicine is a potentially very risky and scary thing.” [22:43]
• Max’s anecdotal defense and personal stories about the positive effects attributed to peptides like BPC-157:
  “My dad took BPC 157 for three days and he said to me, Max, this is the first time in four months I haven’t taken a painkiller.” [15:23]
• Sharp exchange on efficacy:
  • Martin: “I would bet anything, no trial of BPC would work.” [19:04]
  • Max: “Okay, I guess we’ll see.” [19:08]
• Consensus: Both agree that patent pirating is bad, but part on the future regulatory path and interpretation of “evidence.”

Key Timestamps

• 00:00–02:28: Guest intros and core theses
• 03:13–04:00: Defining peptides and pharma skepticism
• 05:45–08:04: Gray market sales, patent piracy, supply chain risk
• 09:19–16:17: BPC-157 debate (efficacy, anecdote v. evidence, upcoming trials)
• 19:43–21:05: Thymosin Alpha 1 and non-FDA US markets
• 22:43–24:33: FDA role; the “white market” harm reduction case
• 25:38–28:33: Can gray markets be shut down? Is the FDA efficient?
• 29:54–31:05: Final warnings, personal liberty vs. regulatory protection
• 31:17–32:26: Superpower’s trial plans and regulatory philosophy
• 32:26–32:44: Final wrap-up and closing statements

Takeaway

The episode provides a nuanced, high-level exploration of the elephant in the innovation-health room: Can a system built for safety and rigor keep pace with the demands and risks of a world increasingly eager to self-experiment, especially with compounds like peptides that straddle the line between miracle and placebo? Shkreli remains the relentless traditionalist, while Marchione is pragmatic about the inevitabilities of consumer demand and real-world use—both agree, however, that medical innovation should be more than just hype, regardless of the source.